{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T07:25:30Z","timestamp":1677914730902},"reference-count":21,"publisher":"Media Sphere Publishing Group","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2015]]},"DOI":"10.17116\/jnevro20151152121-29","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T09:32:52Z","timestamp":1460626372000},"page":"21","source":"Crossref","is-referenced-by-count":1,"title":["Clinical experience and perspectives of using asenapine in stopping acute endogenous psychosis"],"prefix":"10.17116","volume":"115","author":[{"given":"G. P.","family":"Panteleeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. V.","family":"Oleichik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. E.","family":"Novozhenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Sokolov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro20151152121-29-1","unstructured":"American Psychiatric Assotiation. The Diagnostic and statistical manual of mental disorder. 4th ed. Washington DC: American Psychiatric Press 1994; 943."},{"key":"key-10.17116\/jnevro20151152121-29-2","doi-asserted-by":"crossref","unstructured":"Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006; 10: 4: 515\u2014531.","DOI":"10.1517\/14728222.10.4.515"},{"key":"key-10.17116\/jnevro20151152121-29-3","doi-asserted-by":"crossref","unstructured":"Tandon R., Jibson M.D. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole. Int J Psychiatry Clin Pract 2005; 9: 3: 204\u2014212.","DOI":"10.1080\/13651500510029192"},{"key":"key-10.17116\/jnevro20151152121-29-4","doi-asserted-by":"crossref","unstructured":"Lublin H., Eberhard J., Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: review of the new generation antipsychotics. Int Clin Psychpharmacol 2005; 20: 183\u2014198.","DOI":"10.1097\/00004850-200507000-00001"},{"key":"key-10.17116\/jnevro20151152121-29-5","doi-asserted-by":"crossref","unstructured":"Kane J.M., Mackle M., Snow-Adami L., Zhao J., Szegedi A. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatr 2011; 72: 3: 349\u2014355.","DOI":"10.4088\/JCP.10m06306"},{"key":"key-10.17116\/jnevro20151152121-29-6","unstructured":"Henderson D.C., Doraiswamy P.M. Prolactin-related and metabolic adverse-effects of atypical antipsychotic agents. J Clin Psychiatr 2008; 69: 32\u201444."},{"key":"key-10.17116\/jnevro20151152121-29-7","doi-asserted-by":"crossref","unstructured":"Potkin S.G., Coen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatr 2007; 68: 1495\u20141500.","DOI":"10.4088\/JCP.v68n1004"},{"key":"key-10.17116\/jnevro20151152121-29-8","doi-asserted-by":"crossref","unstructured":"Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009; 63: 12: 1762\u20141784.","DOI":"10.1111\/j.1742-1241.2009.02228.x"},{"key":"key-10.17116\/jnevro20151152121-29-9","doi-asserted-by":"crossref","unstructured":"Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsych Dis Treatment 2011; 7: 325\u2014339.","DOI":"10.2147\/NDT.S16077"},{"key":"key-10.17116\/jnevro20151152121-29-10","doi-asserted-by":"crossref","unstructured":"Shahid M., Walker G.B., Zorn S.H., Wong E.H.F. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Clin Psychopharmacol 2009; 23: 65\u201473.","DOI":"10.1177\/0269881107082944"},{"key":"key-10.17116\/jnevro20151152121-29-11","unstructured":"Andreev B.V. Atipichnye antipsikhoticheskie sredstva novogo pokoleniya: fokus na mul'tiretseptornosti. Psikhiatr i psikhofarmako\u00adter 2013; 14: 6: 24\u201429."},{"key":"key-10.17116\/jnevro20151152121-29-12","unstructured":"Schloemaker J., Stet L., Vrijland D., Naber D., Panagides J., Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry 2012; 45: 196\u2014203."},{"key":"key-10.17116\/jnevro20151152121-29-13","doi-asserted-by":"crossref","unstructured":"Buchanan R.W., Panagides J., Zhao J., Phiri P., den Hollander W., Ha X., Kouassi A., Alphs L., Schooler N., Szegedi A., Cazorla P. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2012; 32: 1: 36\u201445.","DOI":"10.1097\/JCP.0b013e31823f880a"},{"key":"key-10.17116\/jnevro20151152121-29-14","doi-asserted-by":"crossref","unstructured":"McIntyre R.S. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother 2010; 10:; 5: 645\u2014649.","DOI":"10.1586\/ern.10.49"},{"key":"key-10.17116\/jnevro20151152121-29-15","doi-asserted-by":"crossref","unstructured":"McIntyre R.S., Cohen M., Zhao J., Alphs L., Macek T.A., Panagides J. Aasenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind placebo-controlled trial. J Affect Dis 2010; 122: 1\u20142: 27\u201438.","DOI":"10.1016\/j.jad.2009.12.028"},{"key":"key-10.17116\/jnevro20151152121-29-16","doi-asserted-by":"crossref","unstructured":"Kane J.M., Cohen M., Zhao J., Alphs L., Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Clin Psychopharmacol 2010; 30: 2: 106\u2014115.","DOI":"10.1097\/JCP.0b013e3181d35d6b"},{"key":"key-10.17116\/jnevro20151152121-29-17","doi-asserted-by":"crossref","unstructured":"Schapel S., Hutmacher M.M., Haig G., Bockbrader H., de Greef R., Preskorn S.H., Lalonde R.L. Exposure-response analysis in patients with schisophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009; 49: 11: 1297\u20141308.","DOI":"10.1177\/0091270009344855"},{"key":"key-10.17116\/jnevro20151152121-29-18","unstructured":"Korteze L., Bressan R.A., Kasl D.D., Mosolov S.N. Lechenie shizofrenii: klinicheskii opyt primeneniya azenapina. Sots i klin psikhiatr 2013; 2: 61\u201466."},{"key":"key-10.17116\/jnevro20151152121-29-19","unstructured":"Petrova N.N., Oleichik I.V. Sovremennye podkhody k kupiruyushchei terapii shizofrenii: opyt primeneniya azenapina. Obozrenie psikhiatr i med psikhol im Bekhtereva 2013; 4: 79\u201489."},{"key":"key-10.17116\/jnevro20151152121-29-20","unstructured":"Shmukler A.B. Azenapin: primenenie v klinicheskoi praktike. Sots i klin psikhiatr 2013; 1: 50\u201454."},{"key":"key-10.17116\/jnevro20151152121-29-21","doi-asserted-by":"crossref","unstructured":"Obermeier M., Mayr A., Schennach-Wolff R., Seem\u00fcller F., M\u00f6ller H.J., Riedel M. Should the PANSS Be Rescaled? Schisophr Bull 2010; 36: 3: 455\u2014460.","DOI":"10.1093\/schbul\/sbp124"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:58:35Z","timestamp":1567778315000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2015\/2\/downloads\/ru\/281997-72982015024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"alternative-id":["jnevro20151152121-29"],"URL":"https:\/\/doi.org\/10.17116\/jnevro20151152121-29","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}